12:00 AM
 | 
May 06, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Innate Pharma preclinical data

In mouse xenograft models of lymphoma, twice-weekly 300 µg injections of 1 of 2 IPH41 mAbs significantly increased median survival vs. IgG1-treated...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >